Spectral Diagnostics (OTCMKTS:EDTXF – Get Free Report) released its quarterly earnings results on Friday. The company reported ($0.01) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.01), Zacks reports. The firm had revenue of $0.28 million for the quarter, compared to analysts’ expectations of $0.42 million.
Spectral Diagnostics Stock Down 2.5%
Shares of Spectral Diagnostics stock traded down $0.02 during trading on Friday, reaching $0.68. The company’s stock had a trading volume of 3,000 shares, compared to its average volume of 9,166. Spectral Diagnostics has a 52-week low of $0.64 and a 52-week high of $1.10. The company has a market cap of $201.15 million, a price-to-earnings ratio of -6.83 and a beta of 0.21. The firm’s 50-day moving average is $0.81 and its two-hundred day moving average is $0.94.
Spectral Diagnostics Company Profile
Spectral Diagnostics Inc is a Canadian medical technology company focused on improving the diagnosis and treatment of sepsis and septic shock. The company develops products designed to identify endotoxin activity, an important factor in certain severe infections and inflammatory conditions.
Its principal diagnostic product is the Endotoxin Activity Assay, a blood test intended to measure a patient’s level of endotoxin activity and help identify individuals who may be at increased risk of developing severe sepsis.
Featured Stories
- Five stocks we like better than Spectral Diagnostics
- Dutch Bros Gave Wall Street What It Wanted, So Why Did the Stock Crater?
- Astera Labs Just Crushed Earnings—So Why Are Analysts Cutting Price Targets?
- Sandisk Shares Are Oversold: Bargain or Value Trap?
- IonQ’s Record Revenue Includes a Big SkyWater Boost: Does That Change the Story?
Receive News & Ratings for Spectral Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spectral Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.
